Summary: Because of this reason, gene fusion protein with albumin has attracted increasing attention in the pharmaceutical industry. HA-GLP1 fused protein (Tanzeum), for treatment of type 2 diabetes, was approved by FDA in 2014. HA-IX clotting factor fused protein (IDELVION), for treatment of hemophilia, was approved by FDA in 2016. By far, more than 60 therapeutic recombinant HA-fusion proteins have been successfully expressed; and some of them have entered medicinal stage.
Agriculture & Food
Business Services
Electronics, IT and Telecoms
Leisure & Tourism
Minerals
Textiles, Clothing, Leather,
Transport & Logistics
